Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of disitamab vedotin in HER2-expressing advanced solid tumors
ChiCTR2200055827Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in Non-hematologic malignancy, sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective response rate. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on ChiCTR2200055827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055827.